Front Line Treatment of Ovarian Cancer Dr. Thomas Herzog

Immunotherapy in Gynecological Cancer Dr. Thomas HerzogПодробнее

Treatment of Recurrent Ovarian Cancer Dr. Thomas HerzogПодробнее

Dr. Herzog on the FDA Approval of Olaparib/Bevacizumab as Frontline Maintenance in Ovarian CancerПодробнее

Role of the Anti-angiogenesis in Ovarian Cancer Dr. Thomas Herzog Day 1 2021Подробнее

Updates on Frontline Treatment of Ovarian Cancer Dr. Thomas Herzog (Day1) 2021Подробнее

Role of PARP Inhibitor in Ovarian Cancer Dr. Thomas HerzogПодробнее

Role of Anti-angiogenesis in Ovarian Cancer Dr. Thomas HerzogПодробнее

Thomas Herzog, MD: Ovarian Cancer Therapy UpdateПодробнее

Duration of Frontline Therapy in Ovarian CancerПодробнее

Dr. Herzog on Novel Therapies in Ovarian CancerПодробнее

First-Line Therapy in Ovarian CancerПодробнее

What Does "Survival" Mean To Ovarian Cancer PatientsПодробнее